×
About 6,502 results

ALLMedicine™ Ocular Hypertension Center

Research & Reviews  2,859 results

ID1 and ID3 are Negative Regulators of TGFβ2-Induced Ocular Hypertension and Compromise...
https://doi.org/10.1167/iovs.62.6.3
Investigative Ophthalmology & Visual Science; Mody AA, Millar JC et. al.

May 3rd, 2021 - In POAG, elevated IOP remains the major risk factor in irreversible vision loss. Increased TGFβ2 expression in POAG aqueous humor and in the trabecular meshwork (TM) amplifies extracellular matrix (ECM) deposition and reduces ECM turnover in the T...

Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039939
Theranostics Luo LJ, Nguyen DD et. al.

Apr 16th, 2021 - Background: Y-27632 is a potent ophthalmic drug for the treatment of ocular hypertension, a globally prevalent eye disease. However, the sustained delivery of Y-27632 by a therapeutic carrier to lesion sites located in the inner segments of the ey...

Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Pa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050785
JAMA Ophthalmology; Kass MA, Heuer DK et. al.

Apr 15th, 2021 - Ocular hypertension is an important risk factor for the development of primary open-angle glaucoma (POAG). Data from long-term follow-up can be used to inform the management of patients with ocular hypertension. To determine the cumulative inciden...

see more →

Drugs  301 results see all →

Clinicaltrials.gov  3,253 results

ID1 and ID3 are Negative Regulators of TGFβ2-Induced Ocular Hypertension and Compromise...
https://doi.org/10.1167/iovs.62.6.3
Investigative Ophthalmology & Visual Science; Mody AA, Millar JC et. al.

May 3rd, 2021 - In POAG, elevated IOP remains the major risk factor in irreversible vision loss. Increased TGFβ2 expression in POAG aqueous humor and in the trabecular meshwork (TM) amplifies extracellular matrix (ECM) deposition and reduces ECM turnover in the T...

Preservative-Free Tafluprost/Timolol Fixed Combo Reduces IOP in Open-Angle Glaucoma
https://www.medscape.com/viewarticle/946281

Apr 27th, 2021 - Takeaway Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on...

Harnessing the tunable cavity of nanoceria for enhancing Y-27632-mediated alleviation o...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039939
Theranostics Luo LJ, Nguyen DD et. al.

Apr 16th, 2021 - Background: Y-27632 is a potent ophthalmic drug for the treatment of ocular hypertension, a globally prevalent eye disease. However, the sustained delivery of Y-27632 by a therapeutic carrier to lesion sites located in the inner segments of the ey...

see more →

News  89 results

Preservative-Free Tafluprost/Timolol Fixed Combo Reduces IOP in Open-Angle Glaucoma
https://www.medscape.com/viewarticle/946281

Apr 27th, 2021 - Takeaway Preservative-free tafluprost (0.0015%)/timolol (0.5%) fixed combination (PF-Taf-T-FC) was effective in reducing intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT), inadequately controlled on...

Ocular Hypertension Trial Supports Watching and Waiting
https://www.medscape.com/viewarticle/949371

Apr 14th, 2021 - Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20-year results of the phase 3 Ocular Hypertension Stud...

Selective Laser Trabeculoplasty's Value Rises During COVID-19
https://www.medscape.com/viewarticle/941990

Dec 8th, 2020 - With the ongoing pandemic, ophthalmologists continue to search for new ways to reduce patient visits and possible virus exposure without sacrificing outcomes. Not surprisingly, monitoring and adjusting eye drop treatments to lower intraocular pres...

EMA Panel Backs Roclanda Eyedrops, New Option for Glaucoma
https://www.medscape.com/viewarticle/941062

Nov 15th, 2020 - The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the fixed-dose combination of latanoprost and netarsudil (Roclanda). The ophthalmic solution is indicated to decrease elevate...

Consider Medication Washout for Some Glaucoma Patients
https://www.staging.medscape.com/viewarticle/929567

Apr 28th, 2020 - NEW YORK (Reuters Health) - Patients with uveitic glaucoma (UG) whose intraocular pressure (IOP) is under control and do not have uveitis recurrence may benefit from ocular hypotensive treatment washout, new findings show. Stopping hypotensive tre...

see more →